We now have a free Apple app—check it out. Visit the Apple Store and download the free digital application for Managed Care, P&T, and Biotechnology Healthcare. Search for "Managed Care," "P&T," "Biotechnology Healthcare," or "MediMedia."
View the new or updated Formulary Kits for Daliresp, Duexis, Onglyza, Viibryd, and Xarelto.
|
 David Nash, M.D, M.B.A., Editor in Chief |
|
David B. Nash, MD, MBA, Dean and The Dr. Raymond C. and Doris N. Grandon Professor, The Jefferson School of Population Health, Philadelphia. From 1996 to 2003, he served as the first Associate Dean for Health Policy at Jefferson Medical College. In 2004, he was named Co-director of the Masters Program in Public Health at Jefferson. View the rest of the Editorial Board here. Contacts:Editor: ssherritze@medimedia.com Advertising: mliberti@medimedia.com Circulation: lgardineer@medimedia.com Production: wpeart@medimedia.com Rate Card BPA Statement Production Specifications Call For Papers P&T Journal is now accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please see our author guidelines below or contact the editor, Sonja Sherritze, via phone 267-685-2779 or email: ssherritze@medimedia.com.
May 2012
COVER STORY
MEDICATION ERRORS | |
 |
| Pharmacy Policies/Procedures: Forms and guidelines |
| Cost Calculators: Exclusive online tools to evaluate your pharmacy costs |
| Links: A comprehensive map of web links to the world of managed care pharmacy |
P&T Community
| Update Your Registration Profile |
| Haven't received your weekly newsletters about the new features on PTcommunity.com? Check your newsletter status by clicking here. Scroll down to the question, 'Check here if you would like to receive our e-newsletter?' and choose 'Yes' or 'No.' |
| Having trouble with the site? Send an email. |
- Expanding Consumer-Directed Health Plans Could Help Cut Overall Health Care Spending
- With More Biosimilars Approved, FDA Urged to Track Adverse Events
- FDA Issues Alert on Potential Dangers of Liberation Therapy for Multiple Sclerosis
- Psychiatrists Say Diagnosis Manual Needs Overhaul
- Potential Savings Through Prevention of Avoidable Chronic Illness Among CalPERS State Active Members
• FDA Updates
• Drug Trials and Comparisons
• Managed Pharmacy Trends
• Legislation and Policy
Digital Edition
- Web-based
- Free to all
- All the words and pictures of the print edition
- Searchable
- Can be downloaded to read offline
Immunotherapy for Advanced Prostate Cancer: A Novel Treatment Option to Improve Survival
Prostate cancer is the second leading cause of cancer death in men in the United States. Sipuleucel-T (Provenge), the first autologous cellular immunotherapy approved by the U. S. Food and Drug Administration, improves survival in men with asymptomatic or minimally symptomatic metastatic castration-resistant (hormone refractory) prostate cancer. This Clinical Brief discusses the epidemiology, natural history, and risk factors for prostate cancer, current diagnosis and treatment modalities, and the emergence of immunotherapy as a novel treatment to improve survival in men with advanced disease. Roger Muller, MD, FACEP, comments on managed care considerations. Safety information and full prescribing information for Sipuleucel-T are also provided.
Comparative Effectiveness Research: Paving the Way for Evidence-Based Decision Making
The second in a series of topics of interest for the managed care community, this brief details the background of comparative effectiveness research (CER) in the United States and discusses the goals versus the uses of CER and the importance of collecting real-world data to support evidence-based medicine. Included are examples of the effective use of CER in clinical practice.
Personalized Medicine: Identifying the Appropriate Patient through Biomarkers in Oncology
The first in a series of topics of interest for the managed care community, this brief discusses the value of biomarkers that can complement or replace existing screening tools to detect cancer at an early stage and, therefore, guide optimum treatment. A history of biomarkers is included as well as a detailed discussion about trastuzumab (Herceptin®), developed with the support of biomarkers, and new biomarkers in development.
Visit Formkit.com to view the newest formulary kits, now available online:
BRILINTA™(ticagrelor) tablets
Please click for full Prescribing Information, including Boxed Warnings, and Medication Guide
DALIRESP® (roflumilast) tablets
Please click here for US Full Prescribing Information
NEW FORMULARY KIT
DUEXIS®(ibuprofen and famotidine)
800 mg/26.6 mg Tablets
Please click for full Prescribing Information, including Boxed Warnings, and Medication Guide
NEW FORMULARY KIT
KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release) tablets
Please click for full Prescribing Information, including Boxed Warnings, and Medication Guide
NEW FORMULARY KIT
LYRICA® (pregabalin)
NEW FORMULARY KIT
Onglyza (saxagliptin) UPDATED FORMULARY KIT
Privigen (Immune Globulin Intravenous [Human], 10% Liquid)
VICTOZA® (liraglutide [rDNA origin] injection)
VIIBRYD® (vilazodone HCl)
Please click here for US Full Prescribing Information
NEW FORMULARY KIT
XARELTO® (rivaroxaban tablets)
Please click here for US Full Prescribing Information
UPDATED FORMULARY KIT
